Progress toward the treatment of arthritis by gene therapy

C. H. Evans; P. D. Robbins

doi:10.3109/07853899509002466

Progress toward the treatment of arthritis by gene therapy

C. H. Evans, P. D. Robbins

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Gene therapy offers several novel advantages to the treatment of arthritis and other joint diseases. Therapeutic genes may be delivered locally to diseased joints or systemically to extra-articular locations using viral or non-viral vectors by ex vivo or in vivo strategies. Pre-clinical experiments with rabbits have demonstrated the utility of using a retrovirus to deliver the human interleukin-1 receptor antagonist to the synovial lining of joints. A human trial based on this principle has been approved by the Recombinant DNA Advisory Committee of NIH and should begin this year.

Original language	English (US)
Pages (from-to)	543-546
Number of pages	4
Journal	Annals of Medicine
Volume	27
Issue number	5
DOIs	https://doi.org/10.3109/07853899509002466
State	Published - 1995
Externally published	Yes

Bibliographical note

Funding Information:
The authors’ work is this area is supported by NIH grant PO1 DK44935, Theragen Inc. and Orthogen GmbH. We thank Mrs Lou Duerring for typing the manuscript.

Keywords

Arthritis
Gene therapy
Interleukin-1 receptor antagonist
Synovium

Publisher link

10.3109/07853899509002466

Find It

Find It at U of M Libraries

Cite this

@article{11e9d8f57da342da933704c7da286594,

title = "Progress toward the treatment of arthritis by gene therapy",

abstract = "Gene therapy offers several novel advantages to the treatment of arthritis and other joint diseases. Therapeutic genes may be delivered locally to diseased joints or systemically to extra-articular locations using viral or non-viral vectors by ex vivo or in vivo strategies. Pre-clinical experiments with rabbits have demonstrated the utility of using a retrovirus to deliver the human interleukin-1 receptor antagonist to the synovial lining of joints. A human trial based on this principle has been approved by the Recombinant DNA Advisory Committee of NIH and should begin this year.",

keywords = "Arthritis, Gene therapy, Interleukin-1 receptor antagonist, Synovium",

author = "Evans, {C. H.} and Robbins, {P. D.}",

note = "Funding Information: The authors{\textquoteright} work is this area is supported by NIH grant PO1 DK44935, Theragen Inc. and Orthogen GmbH. We thank Mrs Lou Duerring for typing the manuscript.",

year = "1995",

doi = "10.3109/07853899509002466",

language = "English (US)",

volume = "27",

pages = "543--546",

journal = "Annals of Medicine",

issn = "0785-3890",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Progress toward the treatment of arthritis by gene therapy

AU - Evans, C. H.

AU - Robbins, P. D.

N1 - Funding Information: The authors’ work is this area is supported by NIH grant PO1 DK44935, Theragen Inc. and Orthogen GmbH. We thank Mrs Lou Duerring for typing the manuscript.

PY - 1995

Y1 - 1995

N2 - Gene therapy offers several novel advantages to the treatment of arthritis and other joint diseases. Therapeutic genes may be delivered locally to diseased joints or systemically to extra-articular locations using viral or non-viral vectors by ex vivo or in vivo strategies. Pre-clinical experiments with rabbits have demonstrated the utility of using a retrovirus to deliver the human interleukin-1 receptor antagonist to the synovial lining of joints. A human trial based on this principle has been approved by the Recombinant DNA Advisory Committee of NIH and should begin this year.

AB - Gene therapy offers several novel advantages to the treatment of arthritis and other joint diseases. Therapeutic genes may be delivered locally to diseased joints or systemically to extra-articular locations using viral or non-viral vectors by ex vivo or in vivo strategies. Pre-clinical experiments with rabbits have demonstrated the utility of using a retrovirus to deliver the human interleukin-1 receptor antagonist to the synovial lining of joints. A human trial based on this principle has been approved by the Recombinant DNA Advisory Committee of NIH and should begin this year.

KW - Arthritis

KW - Gene therapy

KW - Interleukin-1 receptor antagonist

KW - Synovium

UR - http://www.scopus.com/inward/record.url?scp=0028875066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028875066&partnerID=8YFLogxK

U2 - 10.3109/07853899509002466

DO - 10.3109/07853899509002466

M3 - Article

C2 - 8541029

AN - SCOPUS:0028875066

SN - 0785-3890

VL - 27

SP - 543

EP - 546

JO - Annals of Medicine

JF - Annals of Medicine

IS - 5

ER -

Progress toward the treatment of arthritis by gene therapy

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this